Technology evaluation: ABX-EGF, Abgenix/Amgen.
Ranson, Malcolm R
Ranson, Malcolm R
Citations
Altmetric:
Abstract
Abgenix and Amgen (formerly Immunex) are developing ABX-EGF, a human monoclonal antibody against the epidermal growth factor receptor, for potential use in the treatment of cancer. ABX-EGF is undergoing phase II trials in patients with renal, colorectal, prostate and non-small-cell lung cancers. By July 2002, phase III trials for these indications were planned to start in 2003.
Authors
Description
Date
2003-10
Publisher
Collections
Keywords
Cancer
Type
Article
Citation
Technology evaluation: ABX-EGF, Abgenix/Amgen. 2003, 5 (5):541-6 Curr. Opin. Mol. Ther.